EVOMMUNE INC (EVMN) — insider trading
Health Care · NYSE
EVOMMUNE INC (EVMN) has 26 reported SEC Form 4 insider transactions in our data, including 2 open-market purchases and 9 open-market sales among the most recent 26 (latest 2026-07-08).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-08 | Carver Kyle | Officer (Chief Financial Officer) | Open-market purchase | 1,000 | $13.26 | $13.3K | Form 4 |
| 2026-07-07 | KIRSCH ARTHUR S | Director | Open-market purchase | 10,000 | $13.30 | $133.0K | Form 4 |
| 2026-06-22 | Pena Luis C. | Director, Officer (President & CEO) | Open-market sale | 7,438 | $22.71 | $168.9K | Form 4 |
| 2026-06-22 | Patel Jeegar Pravinkumar | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 1,488 | $0.00 | $0 | Form 4 |
| 2026-06-22 | Patel Jeegar Pravinkumar | Officer (Chief Scientific Officer) | Open-market sale | 1,488 | $22.50 | $33.5K | Form 4 |
| 2026-06-22 | Patel Jeegar Pravinkumar | Officer (Chief Scientific Officer) | Option exercise / conversion | 1,488 | $3.84 | $5.7K | Form 4 |
| 2026-06-22 | Drew Janice Suzann | Officer (Chief of Dev. Operations) | Option exercise / conversion (derivative) | 16,161 | $0.00 | $0 | Form 4 |
| 2026-06-22 | Drew Janice Suzann | Officer (Chief of Dev. Operations) | Option exercise / conversion (derivative) | 3,839 | $0.00 | $0 | Form 4 |
| 2026-06-22 | Drew Janice Suzann | Officer (Chief of Dev. Operations) | Open-market sale | 20,000 | $22.63 | $452.6K | Form 4 |
| 2026-06-22 | Drew Janice Suzann | Officer (Chief of Dev. Operations) | Option exercise / conversion | 16,161 | $2.99 | $48.3K | Form 4 |
| 2026-06-22 | Drew Janice Suzann | Officer (Chief of Dev. Operations) | Option exercise / conversion | 3,839 | $3.84 | $14.7K | Form 4 |
| 2026-06-02 | Cohen David E | Director | Grant / award / vesting (derivative) | 15,673 | $0.00 | $0 | Form 4 |
| 2026-06-02 | Cohen David E | Director | Open-market sale | 600 | $21.38 | $12.8K | Form 4 |
| 2026-06-02 | Cohen David E | Director | Open-market sale | 5,456 | $20.21 | $110.3K | Form 4 |
| 2026-06-02 | KIRSCH ARTHUR S | Director | Grant / award / vesting (derivative) | 15,673 | $0.00 | $0 | Form 4 |
| 2026-06-02 | MCGRAW BENJAMIN F III | Director | Grant / award / vesting (derivative) | 15,673 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Pena Luis C. | Director, Officer (President & CEO) | Open-market sale | 16,787 | $22.74 | $381.7K | Form 4 |
| 2026-06-01 | Patel Jeegar Pravinkumar | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 13,512 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Patel Jeegar Pravinkumar | Officer (Chief Scientific Officer) | Open-market sale | 16,687 | $22.74 | $379.5K | Form 4 |
| 2026-06-01 | Patel Jeegar Pravinkumar | Officer (Chief Scientific Officer) | Option exercise / conversion | 13,512 | $3.84 | $51.9K | Form 4 |
| 2026-05-28 | Carver Kyle | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 15,000 | $0.00 | $0 | Form 4 |
| 2026-05-28 | Carver Kyle | Officer (Chief Financial Officer) | Open-market sale | 18,175 | $22.84 | $415.1K | Form 4 |
| 2026-05-28 | Carver Kyle | Officer (Chief Financial Officer) | Option exercise / conversion | 15,000 | $2.99 | $44.9K | Form 4 |
| 2026-05-28 | Moss Gregory S. | Officer (Chief Business & Legal Officer) | Option exercise / conversion (derivative) | 14,223 | $0.00 | $0 | Form 4 |
| 2026-05-28 | Moss Gregory S. | Officer (Chief Business & Legal Officer) | Open-market sale | 14,223 | $22.83 | $324.7K | Form 4 |
| 2026-05-28 | Moss Gregory S. | Officer (Chief Business & Legal Officer) | Option exercise / conversion | 14,223 | $1.71 | $24.3K | Form 4 |
Ask the chat about EVMN's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: EVOMMUNE INC (EVMN).
Last updated 2026-07-08 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.